Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158767 | 0.80 | — | — | |
| SCHEMBL16214719 | 0.79 | LMNA (0.36) | GAA | |
| SCHEMBL28375445 | 0.78 | GAA (0.34) | GAA | |
| SCHEMBL368635 | 0.78 | GAA (0.34) | GAA | |
| SCHEMBL609525 | 0.78 | LMNA (0.39) | GAA | |
| SCHEMBL28187342 | 0.76 | ALDH1A1 (0.48) | GAA | |
| SCHEMBL1964653 | 0.76 | GAA (0.33) | GAA | |
| Hydrochloric Acid SCHEMBL11627695 | 0.76 | LMNA (0.38) | GAA | |
| SCHEMBL608106 | 0.74 | CA2 (0.36) | — | |
| SCHEMBL33483 | 0.74 | GAA (0.32) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | SMITHKLINE BEECHAM PLC | 2005-12-29 | — | — | US | disclosed |
| EP-1389187-A4 | PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID | RANBAXY LAB LTD (IN) | 2005-03-16 | — | — | EP | disclosed |
| US-20050020561-A1 | Process for the preparation of cefpodoxime acid | RANBAXY LABORATORIES LIMITED (IN) | 2005-01-27 | — | — | US | disclosed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | disclosed |
| EP-1389187-A2 | PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID | Ranbaxy Laboratories Limited (IN) | 2004-02-18 | — | — | EP | disclosed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
| WO-2002083634-A2 | PROCESS FOR THE PREPARATION OF CEFPODOXIME ACID | RANBAXY LABORATORIES LIMITED (IN) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020561-A1 | Process for the preparation of cefpodoxime acid | CYP2F1, CYP4F11, CYP51A1 | GAA 802/4885 |
| US-20050288376-A1 | Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted N-hydroxyformamides | CD22, CD2, NEU3 | GAA 4211/4885 |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | GAA 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.